Abstract
Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v. 3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective responses were seen in 14/24 (58%) patients with regimen A (4 complete) and 6/24 (25%) with regimen B (1 complete) (P less than 0.02). The median duration of response was 14 months with regimen A and 6.5 months with regimen B. The median duration of survival was 20 months and 8 months respectively (P less than 0.01). The toxicity was similar with each regimen. There was no evidence of deterioration in left ventricular ejection fraction nor congestive heart failure in any patient. It is concluded that when given at 3-weekly intervals adriamycin is a more effective treatment for advanced breast cancer at higher rather than lower dosage.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chlebowski R. T., Pugh R., Weiner J. M., Block J. B., Bateman J. R. Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. Cancer. 1983 Aug 15;52(4):606–609. doi: 10.1002/1097-0142(19830815)52:4<606::aid-cncr2820520405>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Creech R. H., Catalano R. B., Shah M. K. An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients. Cancer. 1980 Aug 1;46(3):433–437. doi: 10.1002/1097-0142(19800801)46:3<433::aid-cncr2820460302>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Bryan R. M., Baker L. H., Gottlieb J. E., Rivkin S. E., Balcerzak S. P., Grumet G. N., Salmon S. E., Moon T. E., Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977 May;39(5):1940–1948. doi: 10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
- Radford J. A., Knight R. K., Rubens R. D. Mitomycin C and vinblastine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1475–1477. doi: 10.1016/0277-5379(85)90241-x. [DOI] [PubMed] [Google Scholar]
- Steiner R., Stewart J. F., Cantwell B. M., Minton M. J., Knight R. K., Rubens R. D. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol. 1983 Nov;19(11):1553–1557. doi: 10.1016/0277-5379(83)90085-8. [DOI] [PubMed] [Google Scholar]